Ocuphire Pharma Inc. (OCUP) Financial Statements (2025 and earlier)
Company Profile
Business Address |
37000 GRAND RIVER AVE. FARMINGTON HILLS, MI 48335 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 41,414 | 47,166 | 50,516 | 42,361 | 39,999 | 39,010 | |||
Cash and cash equivalents | 41,409 | 47,161 | 50,501 | 42,350 | 39,977 | 38,988 | |||
Short-term investments | 5 | 5 | 15 | 11 | 22 | 22 | |||
Receivables | 1,358 | 1,924 | 926 | 10,132 | 135 | 2,834 | |||
Prepaid expense | 1,027 | 1,471 | 997 | 433 | 687 | 1,010 | |||
Other current assets | 87 | 89 | 102 | 51 | 45 | 78 | |||
Other undisclosed current assets | 948 | 1,194 | 1,407 | 1,211 | 2,595 | 2,467 | |||
Total current assets: | 44,834 | 51,844 | 53,948 | 54,188 | 43,461 | 45,399 | |||
Noncurrent Assets | |||||||||
Property, plant and equipment | 3 | 4 | 5 | ||||||
Total noncurrent assets: | 3 | 4 | 5 | ||||||
TOTAL ASSETS: | 44,834 | 51,844 | 53,948 | 54,191 | 43,465 | 45,404 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 4,124 | 5,713 | 3,968 | 3,816 | 5,761 | 4,154 | |||
Accounts payable | 634 | 2,064 | 2,153 | 1,890 | 2,323 | 2,221 | |||
Accrued liabilities | 3,490 | 3,649 | 1,815 | 1,926 | 3,438 | 1,933 | |||
Derivative instruments and hedges, liabilities | 74 | 74 | 74 | 93 | |||||
Total current liabilities: | 4,198 | 5,787 | 4,042 | 3,909 | 5,761 | 4,154 | |||
Noncurrent Liabilities | |||||||||
Total liabilities: | 4,198 | 5,787 | 4,042 | 3,909 | 5,761 | 4,154 | |||
Equity | |||||||||
Equity, attributable to parent | 40,636 | 46,057 | 49,906 | 50,282 | 37,704 | 41,250 | |||
Common stock | 3 | 3 | 2 | 2 | 2 | 2 | |||
Additional paid in capital | 136,970 | 134,626 | 131,370 | 126,951 | 119,934 | 118,519 | |||
Accumulated deficit | (96,337) | (88,572) | (81,466) | (76,671) | (82,232) | (77,271) | |||
Total equity: | 40,636 | 46,057 | 49,906 | 50,282 | 37,704 | 41,250 | |||
TOTAL LIABILITIES AND EQUITY: | 44,834 | 51,844 | 53,948 | 54,191 | 43,465 | 45,404 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 1,112 | 1,711 | 1,691 | 11,935 | 3,674 | 1,749 | ||
Gross profit: | 1,112 | 1,711 | 1,691 | 11,935 | 3,674 | 1,749 | ||
Operating expenses | (9,440) | (9,419) | (7,120) | (5,549) | (9,063) | (7,880) | ||
Operating income (loss): | (8,328) | (7,708) | (5,429) | 6,386 | (5,389) | (6,131) | ||
Nonoperating income | 563 | 602 | 632 | 517 | 428 | 340 | ||
Other nonoperating income | 563 | 602 | 613 | 456 | 428 | 340 | ||
Income (loss) from continuing operations before equity method investments, income taxes: | (7,765) | (7,106) | (4,797) | 6,903 | (4,961) | (5,791) | ||
Other undisclosed loss from continuing operations before income taxes | (1,328) | |||||||
Income (loss) from continuing operations before income taxes: | (7,765) | (7,106) | (4,797) | 5,575 | (4,961) | (5,791) | ||
Income tax expense (benefit) | 2 | (14) | ||||||
Net income (loss) available to common stockholders, diluted: | (7,765) | (7,106) | (4,795) | 5,561 | (4,961) | (5,791) |
Comprehensive Income ($ in thousands)Annual | Quarterly
9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
---|---|---|---|---|---|---|---|---|
Net income (loss): | (7,765) | (7,106) | (4,795) | 5,561 | (4,961) | (5,791) | ||
Comprehensive income (loss), net of tax, attributable to parent: | (7,765) | (7,106) | (4,795) | 5,561 | (4,961) | (5,791) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.